Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corgentech (CGTK) -- Ignore unavailable to you. Want to Upgrade?

To: Archie Meeties who wrote (17)	11/18/2004 8:10:04 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 39

Archimedes, Sorry to hit you with a question, but now you've revealed yourself an expert. Have you heard of the Holly Graft System, a totally artificial coronary graft soon to seek public money and founded by Manny V.? sec.gov Thoughts? Company has a cool name. Like a vegetable. W

To: Archie Meeties who wrote (17)	11/18/2004 11:56:47 PM
From: tuck	Read Replies (1) \| Respond to of 39

CGTK is involved with all three. PIII for the PBG and CABG indications, and PI/II for the AV grafts for hemodialysis indication. It was the latter I was referring to; sorry if I was not clear about that. shareholder.com Your answer regarding real veins in good condition being preferred to artificial ones did help, though, thanks. Though the phrase "AV grafts are notorious sob's" leads me to ask "in what way, precisely (if different from the simple fact that so many eventually fail)?" Also, I appreciate your reply regarding the information supplied by IVUS and by angiography. Since we're stuck with angiography as the determinant of the primary endpoint, do you have any insight on its ability to precisely measure the 75% occlusion ratio, differentiating well between patients with 74% occlusion and 76%? I would guess that the NDA would contain each patient's record, so the statisticians can look closely at the close calls, but . . . since the PII was single site, and the PIIIs are multi-site, we also have inter-site variability thrown in (hence my citation of the abstract concerning that issue in the Valuation post I made (adding the caveat that QCA -- the technique that is the subject of said abstract -- may not be the form being used here)). TIA & Cheers, Tuck